Contineum Therapeutics, Inc. (CTNM)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice
Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Contineum Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Marc Larkins Johnson & Johnson | 1.98M | $34.85M | $14.23M | -$20.62M | -59.17% |
| KM Kristin Mariani Janus Henderson Group PLC | 2.45M | $27.91M | $17.34M | -$10.57M | -37.87% |
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 20,600 | $269,036 | $145,848 | -$123,188 | -45.79% |
| CD Charlie Durham Sterling Capital Management LLC | 542 | $8,883 | $4,411.88 | -$4,471.12 | -50.33% |
 Point72 Asset Management LP Point72 Asset Management LP | 25,779 | $294,653.98 | $203,654.1 | -$90,999.88 | -30.88% |
Contineum Therapeutics, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Joel Beatty Baird | 21,463.51 | $296,625.75 | $151,639.72 | -$144,986.03 | -48.88% |
Contineum Therapeutics, Inc. (CTNM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Contineum Therapeutics, Inc. ever had a stock split?
Contineum Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Carmine N. Stengone CEO | NASDAQ (NGS) Exchange | 21217B100 CUSIP |
| US Country | 51 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical entity steeped in the research and development of innovative oral small molecule treatments. The company's focus is on addressing unmet medical needs within neuroscience, inflammation, and immunology. Initially known as Pipeline Therapeutics, Inc., it underwent a rebranding to Contineum Therapeutics, Inc. in November 2023. Founded in 2009, the company has established its headquarters in San Diego, California, positioning itself at the forefront of developing therapies that target complex diseases with the potential to significantly impact patient care.
Products and Services
PIPE-791: At the core of Contineum Therapeutics’ pipeline is PIPE-791, a pioneering oral small molecule designed to inhibit the lysophosphatidic acid 1 receptor (LPA1R). This novel compound demonstrates promising brain penetrance capabilities, making it a significant candidate for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-791 stands out for its unique mechanism of action and its potential to address the profound challenges posed by these complex diseases.
PIPE-307: Another notable candidate in Contineum's portfolio is PIPE-307, a selective small molecule inhibitor targeting the muscarinic type 1 M1 receptor. This compound is being developed as a therapeutic option for individuals suffering from depression and relapsing-remitting MS. By focusing on the M1 receptor, PIPE-307 aims to provide a novel approach to managing these conditions, potentially offering a new lease on life for patients grappling with the debilitating effects of depression and MS.
CTX-343: Rounding out Contineum’s innovative suite of molecules is CTX-343, a peripherally-restricted LPA1R antagonist. While details of its specific indications are more limited, its development underscores Contineum Therapeutics’ commitment to exploring new frontiers in medicine. By expanding its research to include peripheral targets, Contineum is broadening its potential impact on the treatment of diseases marked by inflammation and immune responses.
Contact Information
